Hunan Er-Kang Pharmaceutical Co (SZSE:300267) ROE % Adjusted to Book Value : 0.21% (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co ROE % Adjusted to Book Value?

Hunan Er-Kang Pharmaceutical Co's ROE % for the quarter that ended in Mar. 2024 was 0.24%. Hunan Er-Kang Pharmaceutical Co's PB Ratio for the quarter that ended in Mar. 2024 was 1.16. Hunan Er-Kang Pharmaceutical Co's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was 0.21%.

Hunan Er-Kang Pharmaceutical Co ROE % Adjusted to Book Value Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co ROE % Adjusted to Book Value Chart

Hunan Er-Kang Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

1.52

2.22

-7.35

0.64

-2.88

Hunan Er-Kang Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															1.49	1.56	-0.67	-13.86	0.21

Competitive Comparison of Hunan Er-Kang Pharmaceutical Co's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Er-Kang Pharmaceutical Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hunan Er-Kang Pharmaceutical Co's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Er-Kang Pharmaceutical Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Hunan Er-Kang Pharmaceutical Co's ROE % Adjusted to Book Value falls into.

Hunan Er-Kang Pharmaceutical Co ROE % Adjusted to Book Value Calculation

Hunan Er-Kang Pharmaceutical Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-3.95%	/	1.37
	=	-2.88%

Hunan Er-Kang Pharmaceutical Co's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.24%	/	1.16
	=	0.21%

Hunan Er-Kang Pharmaceutical Co ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » ROE % Adjusted to Book Value

Traded in Other Exchanges

N/A

Address

Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331

Website

http://www.hnerkang.com

Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines